Purpose: Our hypothesis is that the addition of bevacizumab to the standard chemotherapy treatment of MPM will improve overall survival and quality of life beyond that achieved with chemotherapy alone.
- Arm 1: Standard Chemotherapy
- Drug: Standard Chemotherapy (Pemetrexed and Cisplatin)
-
- Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation Day 1 (D1=D22, 6 cycles)
- Cisplatin 75 mg/m² Day 1 (D1=D22, 6 cycles)
- Arm 2: Standard Chemotherapy + bevacizumab (Avastin)
- Drug: Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab
-
- Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation D1 (D1=D22, 6 cycles)
- Cisplatin 75 mg/m2 D1 (D1=D22, 6 cycles)
- Bevacizumab 15 mg/kg D1 (D1=D22, until progression)